new_0222_0417|TALS|0|ps_ratio|price_to_book_value|peg_ratio|price|short_interest|dividend_yield|earning_yield|market_cap|pe_ratio|consensus_recommendation|price_target_num_est|price_target|sales_est_1y|sales_est_0y|eps_est_1y|eps_est_0y|ebitda_est_0y|ebitda_est_1y|revenues|ebitda|net_income|price_next_month|price_second_month
new_0222_0417|TALS|1|Talaris Therapeutics Inc PS Ratio|Talaris Therapeutics Inc Price to Book Value|Talaris Therapeutics Inc PEG Ratio|Talaris Therapeutics Inc Price (USD)|Talaris Therapeutics Inc Short Interest|Talaris Therapeutics Inc Dividend Yield|Talaris Therapeutics Inc Earnings Yield|Talaris Therapeutics Inc Market Cap (USD)|Talaris Therapeutics Inc PE Ratio|Talaris Therapeutics Inc Consensus Recommendation|Talaris Therapeutics Inc Price Target Num Estimates|Talaris Therapeutics Inc Price Target (USD)|Talaris Therapeutics Inc Revenue Estimates for Next Fiscal Year (USD)|Talaris Therapeutics Inc Revenue Estimates for Current Fiscal Year (USD)|Talaris Therapeutics Inc EPS Estimates for Next Fiscal Year (USD)|Talaris Therapeutics Inc EPS Estimates for Current Fiscal Year (USD)|Talaris Therapeutics Inc EBITDA Estimates for Current Fiscal Year (USD)|Talaris Therapeutics Inc EBITDA Estimates for Next Fiscal Year (USD)|Talaris Therapeutics Inc Revenue (Quarterly) (USD)|Talaris Therapeutics Inc EBITDA (Quarterly) (USD)|Talaris Therapeutics Inc Net Income (Quarterly) (USD)||
new_0222_0417|TALS|2|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_price|figure_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_whole_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0417|TALS|4|quarterly|daily|quarterly|daily|monthly|daily|daily|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0417|TALS|5||1.43827160494||1.44221105528|15.4117647059|1.44221105528|1.44221105528|1.44221105528||14.3529411765|40.6666666667|40.6666666667|63|50.8|32.1666666667|21.4444444444|48.8|61||91.3333333333|91.3333333333||
new_0222_0417|TALS|6||162||199|17|199|199|199||17|6|6|4|5|6|9|5|4||6|6||
new_0222_0417|TALS|7|daily|daily|daily|market_daily|daily|daily|daily|daily|daily|daily|daily|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly||
new_0222_0417|TALS|20200315||||||||||||||||||||-4.882|-4.848||
new_0222_0417|TALS|20200615||||||||||||||||||||-4.636|-4.663||
new_0222_0417|TALS|20200915||||||||||||||||||||-6.009|-6.417||
new_0222_0417|TALS|20201215||||||||||||||||||||-6.71|-6.779||
new_0222_0417|TALS|20210315||||||||||||||||||||-8.87|-9.299||
new_0222_0417|TALS|20210515||||16.25|31988||-6.5736|670.0996||||||||||||||15.28|16.07
new_0222_0417|TALS|20210615||2.2292||16.8|24406||-6.3584|694.0114||1.25|4|29.25|||-1.87|-1.58|-48.0181|-59.0565||-10.924|-11.352|17.05|14.69
new_0222_0417|TALS|20210715||2.1109||13.91|697169||-9.0451|564.344||1.25||||||-1.73|-48.0181|-59.0565||||14.07|13.81
new_0222_0417|TALS|20210815||2.1836||14.12|700120||-8.9106|583.8041||1.25|4|29.25|||-1.88|-1.73|-49.1012|-60.3971||||14.63|11.61
new_0222_0417|TALS|20210915||1.8929||12.24|779225||-10.2792|506.0738||||||||||||-12.89|-12.941|12.7|13.56
new_0222_0417|TALS|20211015||2.3028||14.46|809070||-8.82|588.7056||1.25||||||||||||14.63|16.89
new_0222_0417|TALS|20211115||2.75||17|979408||-7.5022|703.0282||1.25|4|29.5|||-1.7167|-1.5667|-49.1012|-65.3794||||16.7|12.96
new_0222_0417|TALS|20211215||2.0026||12.38|1089803||-10.3019|511.9699||1.25|||||-1.65|-1.6433|-49.1012|||||13.61|15.29
new_0222_0417|TALS|20220115||2.6788||16.56|1447047||-7.7016|684.8322||1.25|4|29.5|||||-65.3794|-73.245||||15.97|9.43
new_0222_0417|TALS|20220215||1.472||9.1|||-14.0151|376.3269||||||||||||||8.81|8.11